Pathological blood lipid and apolipoprotein alterations following long-term anabolic androgenic steroid (AAS) use

F.M. Grace, N. Sculthorpe, M. Graham, J.S. Baker, M. Edwards, B. Davies

Research output: Contribution to journalMeeting Abstract

Abstract

With the huge market potential for testosterone therapy, information regarding the long-term health effects of AAS administration is of paramount importance.

Aim
The present study addresses the effects of such prolonged administration of supraphysiological AAS doses on cholesterol subfractions and apolipoproteins.

Methods
Subjects were divided into four distinct groups; (A) AAS users (n 8) who were still using at time of testing; (B) AAS users (n 8) who had been abstinent for a period greater than three months (mean SD: 5 2.3 months), (C) bodybuilding controls
(n 8) who did not use any pharmacological ergogenic aids, and (D) sedentary male controls (n 8). AAS use was confirmed through the measurement of Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Sex Hormone Binding Globulin. Data was analysed using the SPSS version 10.0 for Windows statistics package using appropriate statistics.
Results
HDL, Apo-AI and Apo-AII were significantly lower, whereas LDL and Apo-B were significantly higher in the AAS-On group, compared with the non-AAS using groups. 
Conclusion
This level of HDL depression is consistent with many previous reports assessing HDL-C in bodybuilders self-administering AAS. Although definitive mechanisms are unknown, the enzyme Hepatic Triglyceride Lipase is thought to play an important role in the catabolism of HDL. However, the lack of a significant
difference between both groups of AAS users for both Apo-AI and Apo-AII suggests that androgen induced decrements may be more prolonged following the long-term administration of these drugs.
Original languageEnglish
Pages (from-to)615-615
Number of pages1
JournalAnnals of Nutrition and Metabolism
Volume47
DOIs
Publication statusPublished - 2003
Externally publishedYes

Fingerprint

Testosterone Congeners
Apolipoproteins
Lipids
Apolipoprotein A-I
Testosterone
Apolipoprotein A-II
Sex Hormone-Binding Globulin
Apolipoproteins B
Luteinizing Hormone
Lipase
Androgens
Steroids
Cholesterol
Hormones
Pharmacology
Liver
Health
Pharmaceutical Preparations

Cite this

@article{34ee9a1245f4409f9b4ab219effbcb73,
title = "Pathological blood lipid and apolipoprotein alterations following long-term anabolic androgenic steroid (AAS) use",
abstract = "With the huge market potential for testosterone therapy, information regarding the long-term health effects of AAS administration is of paramount importance.AimThe present study addresses the effects of such prolonged administration of supraphysiological AAS doses on cholesterol subfractions and apolipoproteins.MethodsSubjects were divided into four distinct groups; (A) AAS users (n 8) who were still using at time of testing; (B) AAS users (n 8) who had been abstinent for a period greater than three months (mean SD: 5 2.3 months), (C) bodybuilding controls(n 8) who did not use any pharmacological ergogenic aids, and (D) sedentary male controls (n 8). AAS use was confirmed through the measurement of Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Sex Hormone Binding Globulin. Data was analysed using the SPSS version 10.0 for Windows statistics package using appropriate statistics.ResultsHDL, Apo-AI and Apo-AII were significantly lower, whereas LDL and Apo-B were significantly higher in the AAS-On group, compared with the non-AAS using groups. ConclusionThis level of HDL depression is consistent with many previous reports assessing HDL-C in bodybuilders self-administering AAS. Although definitive mechanisms are unknown, the enzyme Hepatic Triglyceride Lipase is thought to play an important role in the catabolism of HDL. However, the lack of a significantdifference between both groups of AAS users for both Apo-AI and Apo-AII suggests that androgen induced decrements may be more prolonged following the long-term administration of these drugs.",
author = "F.M. Grace and N. Sculthorpe and M. Graham and J.S. Baker and M. Edwards and B. Davies",
year = "2003",
doi = "10.1159/000073824",
language = "English",
volume = "47",
pages = "615--615",
journal = "Annals of Nutrition and Metabolism",
issn = "0250-6807",
publisher = "Karger Publishers",

}

Pathological blood lipid and apolipoprotein alterations following long-term anabolic androgenic steroid (AAS) use. / Grace, F.M.; Sculthorpe, N.; Graham, M.; Baker, J.S.; Edwards, M.; Davies, B.

In: Annals of Nutrition and Metabolism, Vol. 47, 2003, p. 615-615.

Research output: Contribution to journalMeeting Abstract

TY - JOUR

T1 - Pathological blood lipid and apolipoprotein alterations following long-term anabolic androgenic steroid (AAS) use

AU - Grace, F.M.

AU - Sculthorpe, N.

AU - Graham, M.

AU - Baker, J.S.

AU - Edwards, M.

AU - Davies, B.

PY - 2003

Y1 - 2003

N2 - With the huge market potential for testosterone therapy, information regarding the long-term health effects of AAS administration is of paramount importance.AimThe present study addresses the effects of such prolonged administration of supraphysiological AAS doses on cholesterol subfractions and apolipoproteins.MethodsSubjects were divided into four distinct groups; (A) AAS users (n 8) who were still using at time of testing; (B) AAS users (n 8) who had been abstinent for a period greater than three months (mean SD: 5 2.3 months), (C) bodybuilding controls(n 8) who did not use any pharmacological ergogenic aids, and (D) sedentary male controls (n 8). AAS use was confirmed through the measurement of Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Sex Hormone Binding Globulin. Data was analysed using the SPSS version 10.0 for Windows statistics package using appropriate statistics.ResultsHDL, Apo-AI and Apo-AII were significantly lower, whereas LDL and Apo-B were significantly higher in the AAS-On group, compared with the non-AAS using groups. ConclusionThis level of HDL depression is consistent with many previous reports assessing HDL-C in bodybuilders self-administering AAS. Although definitive mechanisms are unknown, the enzyme Hepatic Triglyceride Lipase is thought to play an important role in the catabolism of HDL. However, the lack of a significantdifference between both groups of AAS users for both Apo-AI and Apo-AII suggests that androgen induced decrements may be more prolonged following the long-term administration of these drugs.

AB - With the huge market potential for testosterone therapy, information regarding the long-term health effects of AAS administration is of paramount importance.AimThe present study addresses the effects of such prolonged administration of supraphysiological AAS doses on cholesterol subfractions and apolipoproteins.MethodsSubjects were divided into four distinct groups; (A) AAS users (n 8) who were still using at time of testing; (B) AAS users (n 8) who had been abstinent for a period greater than three months (mean SD: 5 2.3 months), (C) bodybuilding controls(n 8) who did not use any pharmacological ergogenic aids, and (D) sedentary male controls (n 8). AAS use was confirmed through the measurement of Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Sex Hormone Binding Globulin. Data was analysed using the SPSS version 10.0 for Windows statistics package using appropriate statistics.ResultsHDL, Apo-AI and Apo-AII were significantly lower, whereas LDL and Apo-B were significantly higher in the AAS-On group, compared with the non-AAS using groups. ConclusionThis level of HDL depression is consistent with many previous reports assessing HDL-C in bodybuilders self-administering AAS. Although definitive mechanisms are unknown, the enzyme Hepatic Triglyceride Lipase is thought to play an important role in the catabolism of HDL. However, the lack of a significantdifference between both groups of AAS users for both Apo-AI and Apo-AII suggests that androgen induced decrements may be more prolonged following the long-term administration of these drugs.

U2 - 10.1159/000073824

DO - 10.1159/000073824

M3 - Meeting Abstract

VL - 47

SP - 615

EP - 615

JO - Annals of Nutrition and Metabolism

JF - Annals of Nutrition and Metabolism

SN - 0250-6807

ER -